Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press77610.17650/1994-4098-2020-16-3-41-45MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИClinical significance of changes in the expression level of markers of surrogate breast cancer subtypes in recurrent and metastatic foci (literature review)Клиническая значимость изменения уровня экспрессии маркеров суррогатных подтипов рака молочной железы в рецидивных и метастатических очагах (обзор литературы)https://orcid.org/0000-0003-4453-6205KruminYu. S.КруминьЮ. С.
Russian Federation

1 Ostrovityanova St., Moscow 117997

Юлия Сергеевна Круминь 

117997 Москва, ул. Островитянова, 1

krumin.iulia@yandex.ruKhaylenkoV. A.ХайленкоВ. А.
Russian Federation

1 Ostrovityanova St., Moscow 117997

23 Kashirskoe Shosse, Moscow 115478

117997 Москва, ул. Островитянова, 1

115478 Москва, Каширское шоссе, 24

KozlovN. A.КозловН. А.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

CheremisG. Yu.ЧеремисГ. Ю.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

PetrovskyyA. V.ПетровскийА. В.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

119991 Москва, ул. Большая Пироговская, 2, стр. 1 

KhaylenkoD. V.ХайленкоД. В.
Russian Federation

1 Ostrovityanova St., Moscow 117997

23 Kashirskoe Shosse, Moscow 115478

117997 Москва, ул. Островитянова, 1

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0001-7728-9533ArtamonovaE. V.АртамоноваЕ. В.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

KovalenkoE. I.КоваленкоЕ. И.
Russian Federation

23 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава РоссииN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России13122020164414512032021120320212020https://ojrs.abvpress.ru/ojrs/article/view/776

The article analyzes data from the world literature for the period from 2005 to 2020 on the relationship between the variability of immunohistochemical expression of estrogen and progesterone receptors, HER2/neu protein and the index of proliferative activity in invasive breast cancer with the course of the disease and the response to medication.

В статье проанализированы данные мировой литературы за период с 2005 по 2020 г., посвященные оценке взаимосвязи изменчивости иммуногистохимической экспрессии рецепторов эстрогена и прогестерона, белка HER2/neu и индекса Ki-67 в инвазивном раке молочной железы с течением заболевания и ответом на проводимое лекарственное лечение.

breast cancerestrogen receptorsprogesterone receptorsKi-67HER2/neusurrogate subtypesрак молочной железырецепторы эстрогенарецепторы прогестеронаKi-67HER2/neuсуррогатные подтипыGlobal health observatory: the data repository. Geneva: World Health Organization, 2018. Available at: http://www.who.int/gho/database/en.Global health observatory: the data repository. Geneva: World Health Organization, 2018. Available at: http://www.who.int/gho/database/en.Perou C.M., Sørlie T., Eisen M.B. et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747–52. DOI: 10.1038/35021093.Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007;8:286–98. DOI: 10.1038/nrg2005.Esteller M. Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 2007;8:286–98. DOI: 10.1038/nrg2005.Zellmer V.R., Zhang S. Evolving concepts of tumor heterogeneity. Cell Biosci 2014;5(69):1–8.Curigliano G., Burstein H.J., Winer E.P. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017;28(8):1700–12. DOI: 10.1093/annonc/mdx308.Curigliano G., Burstein H.J., Winer E.P. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017;28(8):1700–12. DOI: 10.1093/annonc/mdx308.Bustreo S., Osella-Abate S., Cassoni P. et al. Ki-67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat 2016;157(2):363–71. DOI: 10.1007/s10549-016-3817-9.Navin N.E., Hicks J. Tracing the tumor lineage. Mol Oncol 2011;4(3):267–83.Guarneri V., Broglio K., Kau S.W. et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2008;24(7):1037–44.Guarneri V., Broglio K., Kau S.W. et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2008;24(7):1037–44.Lower E.E., Glass E., Blau R. et al. HER2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009;113:301–6 DOI: 10.1007/s10549-008-9931-6.Lower E.E., Glass E., Blau R. et al. HER2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009;113:301–6 DOI: 10.1007/s10549-008-9931-6.Allison K.H., Hammond M.E.H., Dowsett M. et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med 2020. DOI: 10.5858/arpa.2019-0904-SA.Allison K.H., Hammond M.E.H., Dowsett M. et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med 2020. DOI: 10.5858/arpa.2019-0904-SA.Colomer R., Aranda-López I., Albanell J. et al. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol 2018;20(7):815–26. DOI: 10.1007/s12094-017-1800-5.Colomer R., Aranda-López I., Albanell J. et al. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol 2018;20(7):815–26. DOI: 10.1007/s12094-017-1800-5.Coates A.S., Winer E.P., Goldhirsch A. et al. Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015;26(8):1533–46. DOI: 10.1093/annonc/mdv221.Coates A.S., Winer E.P., Goldhirsch A. et al. Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015;26(8):1533–46. DOI: 10.1093/annonc/mdv221.Balic M., Thomssen C., Würstlein R. et al. St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. Breast Care (Basel) 2019;14(2):103–10.Balic M., Thomssen C., Würstlein R. et al. St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. Breast Care (Basel) 2019;14(2):103–10.Guarneri V., Piacentini F., Ficarra G. et al. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol 2008;20: 1193–8.Guarneri V., Piacentini F., Ficarra G. et al. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol 2008;20: 1193–8.Lower E.E., Glass E., Blau R., Harman S. HER2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009;113(2):301–6.Lower E.E., Glass E., Blau R., Harman S. HER2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009;113(2):301–6.Lower E.E., Khan S., Kennedy D., Baughman R.P. Discordance of the estrogen receptor and HER2/neu in breast cancer from primary lesion to first and second metastatic site. Breast Cancer (Dove Med Press) 2017;9:515–20. DOI: 10.2147/BCTT.S137709.Lower E.E., Khan S., Kennedy D., Baughman R.P. Discordance of the estrogen receptor and HER2/neu in breast cancer from primary lesion to first and second metastatic site. Breast Cancer (Dove Med Press) 2017;9:515–20. DOI: 10.2147/BCTT.S137709.Kolyadina I.V., Andreeva Yu.Yu., Frank G.A., Poddubnaya I.V. The role of biological heterogeneity in recurrent and metastatic breast cancer. Arkhiv patologii = Archive of Pathology 2018;(6):62–7. (In Russ.)].Колядина И.В., Андреева Ю.Ю., Франк Г.А., Поддубная И.В. Роль биологической гетерогенности при рецидивирующем и метастатическом раке молочной железы. Архив патологии 2018;(6):62–7.Erdem G.U., Altundag K., Ozdemir N.Y. et al. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer. J BUON 2017;22(2):365–76.Erdem G.U., Altundag K., Ozdemir N.Y. et al. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer. J BUON 2017;22(2):365–76.Lower E.E., Glass E.L., Bradley D.A. et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005;90(1):65–70.Lower E.E., Glass E.L., Bradley D.A. et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005;90(1):65–70.Li F.Y., Wu S.G., Zhou J. et al. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. PLoS One 2014;9(2):87264.Li F.Y., Wu S.G., Zhou J. et al. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. PLoS One 2014;9(2):87264.Cheang M.C., Chia S.K., Voduc D. et al. Ki-67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Natl Cancer Inst 2009;101(10):736–50. DOI: 10.1093/jnci/djp082.Amir E., Miller N., Geddie W. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012;30:587–92. DOI: 10.1200 JCO.2010.33.5232.Amir E., Miller N., Geddie W. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012;30:587–92. DOI: 10.1200 JCO.2010.33.5232.Cejalvo J.M., Martinez de Dueñas E., Galván P. et al. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res 2017;77(9):2213–21.Cejalvo J.M., Martinez de Dueñas E., Galván P. et al. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res 2017;77(9):2213–21.Houssami N., Macaskill P., von Minckwitz G. et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 2012;48(18):3342–54. DOI: 10.1016/j.ejca.2012.05.023.Houssami N., Macaskill P., von Minckwitz G. et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 2012;48(18):3342–54. DOI: 10.1016/j.ejca.2012.05.023.Yang Y., Im S., Keam B. et al. Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. BMC Cancer 2016;16(515):1–10. DOI: 10.1186/s12885-016-2500-1.Yang Y., Im S., Keam B. et al. Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses. BMC Cancer 2016;16(515):1–10. DOI: 10.1186/s12885-016-2500-1.Guarneri V., Broglio K., Kau S.W. et al. Prognostic value of pathologic completeresponse after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24(7):1037–44.response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24(7):1037–44.Ring A.E., Smith I.E., Ashley S. et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004;91(12):2012–7. DOI: 10.1038/sj.bjc.6602235.Ring A.E., Smith I.E., Ashley S. et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004;91(12):2012–7. DOI: 10.1038/sj.bjc.6602235.Tőkés T., Tőkés A.M., Szentmártoni G. et al. Prognostic and clinicopathological correlations of cell cycle marker expressions before and after the primary systemic therapy of breast cancer. Pathol Oncol Res 2019;26(3):1499–510. DOI: 10.1007/s12253-019-00726-w.Tőkés T., Tőkés A.M., Szentmártoni G. et al. Prognostic and clinicopathological correlations of cell cycle marker expressions before and after the primary systemic therapy of breast cancer. Pathol Oncol Res 2019;26(3):1499–510. DOI: 10.1007/s12253-019-00726-w.Bonacho T., Rodrigues F., Liberal J. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review. Biotech Histochem 2020;95(2):71–91.Bonacho T., Rodrigues F., Liberal J. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review. Biotech Histochem 2020;95(2):71–91.Zenzola V., Cabezas-Quintario M.A., Arguelles M. et al. Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer. Clin Transl Oncol 2018;20(11):1448–54. DOI: 10.1007/s12094-018-1877-5.Zenzola V., Cabezas-Quintario M.A., Arguelles M. et al. Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer. Clin Transl Oncol 2018;20(11):1448–54. DOI: 10.1007/s12094-018-1877-5.Robertson S., Rönnlund C., de Boniface J., Hartman J. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant. Breast Cancer Res Treat 2019;174(3):795–805. DOI: 10.1007/s10549-018-05119-2.Denkert C., Wienert S., Poterie A. et al. Standardized evaluation of tumorinfiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathol 2016;29(10):1155.Lindström L.S., Karlsson E., Wilking U.M. et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012;30(21):2601–8.American Society of Clinical Oncology (ASCO): Tumor Marker Tests (2018, June 15). Retrieved October 18, 2018. Available at: https://www.cancer.net/ navigating-cancer-care/diagnosing-cancer/ tests-and-procedures/tumor-marker-tests.American Society of Clinical Oncology (ASCO): Tumor Marker Tests (2018, June 15). Retrieved October 18, 2018. Available at: https://www.cancer.net/ navigating-cancer-care/diagnosing-cancer/ tests-and-procedures/tumor-marker-tests.Amir E., Clemons M., Purdie C.A. et al. Tissue confirmation of disease recurrence in 9 breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 2012;38(6):708–14. DOI: 10.1016/j.ctrv.2011.11.006.Amir E., Clemons M., Purdie C.A. et al. Tissue confirmation of disease recurrence in 9 breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 2012;38(6):708–14. DOI: 10.1016/j.ctrv.2011.11.006.